Form 4: Zivo Bioscience Director's Affiliate Boosts Stake

A director and 10% owner of Zivo Bioscience, Mark E. Strome, indirectly acquired additional common stock and warrants through an affiliated entity, Strome Mezzanine Fund II, LP.

Summary

• Mark E. Strome, a Director and 10% owner of Zivo Bioscience, Inc. (ZIVO), along with affiliated entities, reported an indirect acquisition of company securities.
• Strome Mezzanine Fund II, LP (SMF II), an entity for which the reporting persons may be deemed to share beneficial ownership, acquired 20,000 shares of common stock at $9.77 per share.
• Following this transaction, SMF II beneficially owns 472,942 shares of common stock.
• SMF II also acquired 2,000 common stock purchase warrants with an exercise price of $9.77, exercisable from February 12, 2026, and expiring on February 11, 2031.
• The reported acquisition price for the derivative security (warrant) was $0.
• After this transaction, SMF II beneficially owns 45,071 common stock purchase warrants.
• The acquisitions were made pursuant to a Securities Purchase Agreement between SMF II and Zivo Bioscience, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director and significant owner increasing their stake typically indicates confidence in the company's future performance, though it's a routine disclosure without new operational details.

Positives

• An insider (Director and 10% owner) increased their stake in the company, which can signal confidence in future prospects.
• The acquisition was made through a Securities Purchase Agreement, indicating a structured investment by a significant shareholder.

Negatives

• The reported acquisition price for the derivative security (warrant) was $0, which might warrant further clarification on the actual cost basis for the warrants.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider buying, especially from a director and significant owner, can often be interpreted by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or that significant positive developments are anticipated. This type of transaction is common across various industries when insiders wish to increase their exposure to their company's equity.

Comparison to Industry Standards

• Insider purchases are a common occurrence across all industries. While the specific amount and price are unique to Zivo Bioscience, the act of a director increasing their stake is generally viewed favorably, similar to how investors might react to insider buying at companies like Tesla (TSLA) or Apple (AAPL), where management's conviction is seen as a strong indicator.
• The acquisition of warrants alongside common stock suggests a long-term bullish outlook, a strategy also employed by investors in growth-oriented companies.

Related Party Transactions

• Strome Mezzanine Fund II, LP, an entity affiliated with Director and 10% owner Mark E. Strome, acquired 20,000 shares of common stock and 2,000 common stock purchase warrants directly from Zivo Bioscience, Inc. via a Securities Purchase Agreement.
• Mark E. Strome, Strome Investment Management, LP, and Strome Group, Inc. are deemed to share voting and investment power for the shares held by SMF II, establishing a related party relationship for this transaction.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive sign of confidence from a significant owner, potentially influencing investor sentiment.

Key Dates

Recommendation

The insider purchase by a director and 10% owner is a positive indicator of confidence in Zivo Bioscience's future. However, a Form 4 filing alone does not provide sufficient operational or financial details to justify a 'buy' or 'strong buy' recommendation. It suggests that existing shareholders may want to hold their positions, and potential investors should conduct further research into the company's fundamentals and strategic direction.

Keywords

Zivo Bioscience, ZIVO, Mark E. Strome, Insider Trading, Form 4, Beneficial Ownership, Stock Purchase, Warrants, Director Ownership, SEC Filing